whether Fosamax (alendronate) and other bisphosphonates increase the risk of atrial fibrillation
See FDA's updated safety analysis concerning bisphophonates and atrial fibrillation
Patients are asking whether Fosamax (alendronate) and other bisphosphonates increase the risk of atrial fibrillation.
This first came up last year when researchers noted an increase in A fib in patients getting IV zoledronic acid (Reclast).
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote